HCP Live November 6, 2023
Very few patients switch off a biosimilar due to adverse effects, according to a new study.
Switching back from a biosimilar to its reference biologic product was not only rare among a cohort of Veterans Affairs patients, but investigators observed that there were no distinct trends of rationale as to why a patient would switch back.
In new data from an abstract presented at the International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Annual Meeting this year, a team of US-based investigators reported data inconclusive to the notion that Veteran patients would primarily switch from a biosimilar product back to its reference biologic product due to a lack of efficacy or safety with the cost-efficient option.
Led by Kelly...
Today's Sponsors
Today's Sponsor